Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF METABOLIC SYNDROME
Document Type and Number:
WIPO Patent Application WO2005018436
Kind Code:
A3
Abstract:
The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) I (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2.

Inventors:
FARRER LINDSAY A (US)
WYSZYNSKI DIEGO F (US)
Application Number:
PCT/US2004/027758
Publication Date:
August 18, 2005
Filing Date:
August 26, 2004
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV BOSTON (US)
FARRER LINDSAY A (US)
WYSZYNSKI DIEGO F (US)
International Classes:
C07H21/04; C12Q1/68; G01N33/50; A61B; (IPC1-7): C07H21/04; C12Q1/68
Other References:
CHEN ET AL: "Effect of the microsomal triglyceride transfer protein -493 G/T polymorphism andtype 2 diabetes mellitus on LDL subfractions", ATHEROSCLEROSIS, vol. 167, April 2003 (2003-04-01), pages 287 - 292, XP002987229
ST-PIERRE ET AL: "Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men", ATHEROSCLEROSIS, vol. 160, 2002, pages 287 - 292, XP002987230
Download PDF: